OKYO PHARMA LTDOKYO
ASignal's systematic analysis rates OKYO as Neutral.
Reflects the latest available analysis · analyzed Oct 26, 2026
The case on OKYO
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.90)
- No debt with $20.59M cash on balance sheet
- Current ratio of 2.43x indicates solid short-term liquidity
- MACD above signal line with positive histogram expansion
- Price above 20-day and 50-day moving averages
- Negative return on equity (-263.78%) and return on assets (-43.10%)
- Zero gross, operating, and net margins
- Negative free cash flow ($-2.10M) and operating cash flow ($-5.94M)
- Negative forward P/E (-2.18x) and negative EV/EBITDA (-6.22x)
- No revenue or earnings growth data available
- Extremely low news and retail sentiment coverage
See the full verdict on OKYO
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes OKYO
Most investors never get a second opinion, let alone several. ASignal runs OKYO past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.